The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

GSK gets EMA Committee positive opinion for its malaria candidate vaccine Mosquirix.....           AbbVie's Technivie gets FDA approval to treat genotype 4 chronic hepatitis C.....           Sanofi and Regeneron's Praluent gets FDA approval to treat high LDL cholesterol in adults.....           Eddingpharm to begin Phase I trial of Brinavess in China.....           EMA accepts Merck's MAA for grazoprevir/elbasvir to treat chronic hepatitis C infection.....           Merck Serono extends collaboration with BioMed X.....           Pulmatrix issued patents covering iSPERSE technology to treat patients with inhaled dry powders.....           Eagle Pharmaceuticals? RTU Bivalirudin NDA accepted for filing by FDA.....           National Pharma Industries introduces new allergy medication Naramin.....           Shire CEO: We're prepared to wait for the right deal.....           Biogen gets beaten up as slowing Tecfidera sales lead it to trim forecast.....           Novartis' newly acquired melanoma combo wins EU recommendation.....           AbbVie falls short on Q2 sales--but don't blame biosimilars, CEO says.....           Cancer docs try to rally public behind plan to fight drug prices.....           UnitedHealth uses newfound scale to negotiate pay-for-performance deals.....           Health Canada approves Theravance's Vibativ for HAP/VAP caused by gram-positive bacteria.....           Amgen submits sNDA to FDA for Kyprolis to treat relapsed multiple myeloma.....           EMA validates Bristol-Myers's two type II variation applications to extend Opdivo indication.....           Lpath gets FDA nod to initiate Phase I lpathomab clinical trial.....           Janssen submits sNDA for Olysio in combination with Sofosbuvir to treat CHC infection.....           TTY Biopharm to market PharmaMar's Aplidin in Taiwan to treat hematological cancers.....           Heron begins second Phase II trial of HTX-011 to treat post-operative pain.....           Eli Lilly's Q2 beats the Street as newer products, animal health buy pitch in.....           RegeneRx gets notice of acceptance for Australian patent for key TB4 peptide fragment.....           Cardiome submits supplemental new drug submission for Aggrastat to Health Canada.....           Acorda awarded grant to study ARCUS Technology in respiratory distress syndrome.....           Tract Therapeutics completes Phase I safety trial using patient?s immune cells to prevent organ rejection.....           Roche clocks fast growth for new meds Perjeta, Esbriet as it girds for biosim rivalries.....           Eli Lilly's Q2 beats the Street as newer products, animal health buy pitch in.....           Bristol-Myers smashes Q2 as hep C meds rake in overseas sales.....           Forecast-beating Valeant ups 2015 guidance with fast-growing Xifaxan in mind.....           The stichting strikes back: Mylan's Dutch foundation snaps up shares to block Teva buy.....           Novartis whacks 3 Sandoz plants, 770 jobs, despite generic units' sales growth.....           Genmab's partner Novartis submits sBLA to FDA for ofatumumab to treat relapsed CLL.....           Johnson & Johnson to challenge Novartis in axial spondyloarthrtis treatment space, says GlobalData.....           Perrigo agrees to buy German dietary supplement brand Yokebe.....           Medimmune, Sheffield University to research in cell factory technology.....           Pfizer expands lease agreement with Kendall Square for research facility.....           Merck?s Keytruda gets European Commission approval to treat advanced melanoma.....           Ablynx expands immuno-oncology collaboration with Merck.....           Novavax reports positive results from Phase I Ebola GP vaccine trial.....           Spero achieves first milestone payment in anti-infective partnership with Roche.....           BMS reports additional Phase IIa data for BMS-955176 to prevent maturation of HIV-1.....           European Commission approves Amgen's Repatha to treat high cholesterol.....           Simulations Plus extends research deal with NIEHS.....           Lysogene, Alcyone Lifesciences enter collaboration for mucopolysaccharidosis type IIIA.....           Should J&J break up? Get ready for a new round of debate.....           Nonprofit snags $5.2M grant to investigate U.S. drug pricing.....           Drugmakers like Gilead, Mylan and Novo--not Big Pharma--are job creators.....           CF specialists up in arms about $259K price for new Vertex med Orkambi.....           Genzyme's Cerdelga success bodes well for Fabry prospect.....           New obesity meds 'pretty safe,' but some side effects bear watching: AdverseEvents.....           Eisai, JCR to discover new CNS treatments using BBB penetration technology.....           Forge enters into pilot study with Janssen to discover new metalloprotein inhibitors.....           MGB Biopharma begins Phase I trial of oral MGB-BP-3 to treat clostridium difficile infections.....           Isis Pharmaceuticals begins Phase I/IIa trial of ISIS-HTT to treat patients with Huntington's disease.....           Cerulean doses first patient in Phase Ib trial of CRLX101-paclitaxel combination in relapsed ovarian cancer.....           Bristol-Myers gets FDA breakthrough therapy status for investigational HIV-1 attachment inhibitor.....           Knight Therapeutics gets exclusive distribution rights of Alimera's Iluvien in Canada to treat DME.....           Erytech reports positive results from Phase II trial of ERY-ASP in pancreatic cancer patients.....           Delcath gets FDA orphan drug status for melphalan to treat cholangiocarcinoma.....           StemCells treats first patient in Phase II HuCNS-SC trial for dry AMD.....           Asahi Kasei gets approval for Xiaflex in Japan to treat Dupuytren's Contracture.....           Novartis looks past dim Q2 results to new Glatopa, Entresto launches.....           Actelion's Opsumit growth heralds smooth switch off aging Tracleer.....           Horizon hikes Depomed offer to $2B in bid for 'friendly' deal talks.....           Novartis CEO predicts a pharma pricing squeeze from insurer M&A.....           Amgen's Neupogen won't face Novartis biosim till September: court.....           Bristol-Myers' next-gen HIV med gets FDA 'breakthrough' designation.....           Alnylam begins Phase III APOLLO-OLE trial of patisiran to treat ATTR amyloidosis.....           Merck gets approval in Europe to extend Kuvan use for children with PKU.....           Bristol-Myers's Phase III RCC trial of Opdivo shows superior overall survival over everolimus.....           Valeant to buy Amoun Pharmaceutical for $800m.....           RegeneRx's GtreeBNT gets Korean approval for Phase IIb/III trial of RGN-259 in patients with DES.....           Ipsen gets FDA approval for Dysport for Injection to treat upper limb spasticity in adults.....           Allergan launches Saphris 2.5 mg sublingual tablets in US.....           Motif?s Iclaprim gets FDA QIDP designation for HABP.....           Cellecta receives NIH SBIR grant to develop validated CRISPR knockout library of guide RNA (sgRNA) sequences.....           Aquinnah Pharma gets $0.5m frants from ALS Association.....           ContraFect gets key patent from USPTO covering new Lysin technology.....           BioLineRx to present successful Phase I/II trial results for new celiac treatment at International Celiac Disease Symposium.....           Recro Pharma reports positive top-line results for Phase II trial of Dex-IN.....           Sanofi preps for 'profitable' dengue vaccine rollout in 20 countries.....           India expands drug pricing with caps for two antibiotics.....           Vast majority of consumers want Medicare to negotiate drug prices.....           Study stopped early as BMS' Opdivo bests Afinitor in kidney cancer.....           New long-acting Baxalta med bests Advate in hemophilia A.....           Bayer homes in on ?10B plastics IPO with plans for summer roadshow.....           AstraZeneca divests non-US rights of Entocort to Tillotts Pharma for $215m.....           AbbVie and C2N's humanized anti-tau antibody gets FDA orphan drug status to treat progressive supranuclear palsy.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
Recent meetings

APS Particle Engineering

13 April 2015 - Dublin

The first stage for successful Pharmaceutical formulation

April continued to be a busy month for APS events with a well-attended and successful two-day joint meeting organised with the Synthesis and Solid State Pharmaceutical Centre (SSPC) which brought together many key opinion leaders from academia and industry providing world leading knowledge and case studies in all key aspects around particle engineering.


Latest News
Professor Frank Fish Memorial Award Lecture 2015
The APS is pleased to support the Professor Frank Fish Memorial Award Lecture 2015. UCL School of Pharmacy Thursday, 15 October 2015 from 17:00 to 19:00 (BST) London, United Kingdom. . The potential and challenge of traditional Chinese medicine to meet unmet clinical needs Professor Tommy (Yung-Chi) Cheng . On Thursday, 15 October 2015 the fourth Frank Fish Memorial lecture entitled 'Potential and challenge of traditional Chinese medicine to meet unmet clinical needs' will be given by Prof. Tommy (Yung-Chi) Cheng from Yale University. We are delighted that a one of the world's leading experts in pharmacology focusing on Traditional Chinese Medicine (TCM) will give this year's lecture.. Time. . 5pm arrivals 5.30pm lecture 6.30pm drinks reception and canapes . Prof. Cheng is Henry Bronson Professor of Pharmacology and the Chairman of the Consortium for the Globalization of Chinese Medicine (CGCM), a network of world-leading universities with an interest in Traditional Chinese Medicine (TCM). In his research he is interested in studying the functional roles and properties of virus-specific proteins in order to design selective antiviral compounds and in exploring the mechanisms of drug resistance development, with a special emphasis on the processes involved in DNA topoisomerase, targeting drugs and nucleoside analogs.. He is particularly well known for his work on PHY906, a TCM preparation composed of four medicinal plants (Scutellaria baicalensis Geori, Glycyrrhiza uralensis Fisch, Paeonia lactiflora Pall and Ziziphus jujube Mill). A combination of these four botanical drugs has been used continuously in TCM for over 1800 years for treating gastrointestinal problems including diarrhoea, nausea, cramps and vomiting. The Professor Frank Fish Memorial Award lectures have been generously funded by Professor Fish's family. Professor Frank Fish was well known in the field of pharmacognosy and phytochemistry, and was Dean at the School of Pharmacy from 1978 - 1988. . For more information, please visit:
Royal Pharmaceutical Society Excellence in Pharmaceutical Science Award
The APS is delighted to support the following announcement from the RPS:. Royal Pharmaceutical Society 'Excellence in Pharmaceutical Science Award'. Sponsored by Ferring'. The Excellence in Pharmaceutical Science Award recognises pharmaceutical scientists who have delivered proactive and innovative projects and initiatives that lead the way in pharmaceutical science.. Examples of previous submissions and projects that would be suitable for submission for the RPS Excellence in Pharmaceutical Science Award include:. Development of novel sub-unit TB vaccines Technologies for the treatment of brain diseases The design of clinically useful oral chelating agents Development of a delivery vehicle for the treatment of brain diseases Development of a new tuberculosis vaccine Antibiotic dosing in critical care Development of a chip to quantify opiates in a clinical setting Anti-doping project for the London 2012 Olympic and Paralympic games. Do you or a colleague deserve recognition for your work? Nominate today. The deadline for nominations is 9am Monday 20 July.. The awards will be presented at the Royal Pharmaceutical Society Awards Dinner on Sunday 13 September 2015 at the ICC, Birmingham on the evening of the RPS Annual Conference..
MONDAY, 29 JUNE 2015
How will you benefit from attending this year’s APS International PharmSci Conference?. . . The deadline for the early bird rate of 31st July 2015 is fast approaching. Register now to benefit from discounted rates of £66 for one day and up to £170 for three days. Additional discounts are available for APS members.. What APS International PharmSci offers you?. Network with broad range of scientists from fellow students up to eminent professors from most of the key UK Universities. Learn about the latest innovative science by attending a variety of sessions demonstrating how Pharmaceutical Scientists are striving to improve patient health globally Understand how Pharmaceutical Science is applied in the Industry and what opportunities this might present for you by engaging with representatives from the Pharmaceutical Industry including Pfizer, Astra Zeneca, GSK and BMS.. UK Pharm Sci includes:. A session by the Student Association of the APS (SAPS)on Increasing your employability after your degree. A session by the APS New Scientists Focus Group offering the opportunity for new scientists to present.. Submit an innovative Bright Idea related to the Pharmaceutical Sciences with the chance to win an award of £500 as a contribution to turn the best idea into reality. View and discuss posters and hear selected abstracts presented on thepodium. Visit the conference exhibition to see and talk to a range of companies offering the latest testing technologies and learn about career opportunities.. Book now at to be part of this leading Pharmaceutical Sciences Conference and gain an insight into the opportunities within Pharmaceutical Sciences..
5th Annual MIBio Conference
FRIDAY, 26 JUNE 2015
MIBio 2015: Stability of biopharmaceuticals – From molecular interactions to successful products. 21st October 2015, Cripps Court, Magdalene College, Cambridge, UK.. The MIBio conference series engages world leading experts from industry and academia in a discussion on how the latest molecular interaction based discoveries can be exploited in biopharmaceutical formulation to produce more effective, patient-friendly and safer therapeutic products. Seven key experts in the field will present during the day on this topic, and, as is traditional in the MIBio series, there will be opportunities for audience participation. We will be inviting abstracts for poster submissions and welcome applications for sponsor and exhibitor slots. We look forward to seeing you at MIBio 2015!. The conference website can be found here: . The MIBio 2015 organising committee is:. Jan Jezek (Arecor). Nicholas J. Darton (Arecor). Tejash Shah (GSK). Stephen Harding (University of Nottingham).
Follow us
Upcoming Events
APS 6th International PharmSci Conference 2015
7 - 9 September 2015
APS Emerging nanomedicine applications in infection, cancer and CNS targeting
10 September 2015
APS 20th Anniversary International Pharmaceutical Photostability Conference 2015
5 - 7 October 2015
APS Board Meeting
13 - 14 October 2015
MIBio 2015: Stability of biopharmaceuticals From molecular interactions to successful products
21 October 2015
Job Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.